Regulatory approval for MGTs is limited to very narrow indications (e.g., trastuzumab is approved for HER2-amplified breast or gastric cancer but not for HER2-amplified biliary or salivary gland cancer), and it is difficult to prescribe MGTs outside of regulatory approval for patients with rare actionable genomic alterations. Here, ERBB2 is linked to gastric cancer.